Xaira joined the Unicorn Club on April 23, 2024, after raising a $1B Series D funding round led by Arch Venture Partners and Foresite Labs. Founded in 2023, the company specializes in AI-enabled drug discovery and development, combining product development, biological and clinical data generation, and AI research to accelerate translational and fundamental drug discovery processes.
Keep reading to explore Xaira’s funding history, key investors, and what’s next for this life sciences tech innovator.
What Is Xaira and What Does It Do?
Xaira is a San Francisco, California, United States-based company focused on leveraging AI for drug discovery and development. The platform integrates biological and clinical data generation with advanced AI methods to streamline translational and fundamental research, enabling the faster and more efficient identification and development of therapeutics.
Xaira operates in the life sciences tech sector, addressing complex challenges in drug R&D, and aims to improve success rates and reduce timelines in pharmaceutical innovation.
How Much Funding Has Xaira Raised?
- Series D
- Amount Raised: $1B
- Date: April 23, 2024
- Lead Investors: Arch Venture Partners, Foresite Labs
- Motivation: To accelerate AI-driven drug discovery, expand operations, and scale platform capabilities.
Total Funding Raised: $1B
Current Valuation: Not publicly disclosed, unicorn status achieved
Latest Funding Date: April 23, 2024
Key Investors
- F-Prime Capital
- Details: Venture capital firm investing in life sciences and technology innovation.
- Investment Focus Areas: Healthcare, biotech, AI-enabled therapeutics.
- Notable Investments: Xaira, Moderna, Thermo Fisher Scientific.
- New Enterprise Associates (NEA)
- Details: Global VC firm supporting early to late-stage technology and healthcare companies.
- Investment Focus Areas: Life sciences, AI, biotech innovation.
- Notable Investments: Xaira, Robinhood, Coursera.
- Arch Venture Partners
- Details: Early-stage venture capital firm focused on transformative biotech and life sciences companies.
- Investment Focus Areas: Drug discovery, therapeutics, AI-driven biotech.
- Foresite Labs
- Details: Investment firm targeting healthcare and life sciences innovation.
- Investment Focus Areas: Biotech, AI in drug development, and medical technologies.
Where Is Xaira’s Headquarters?
Xaira is headquartered in San Francisco, California, United States, a leading hub for AI, biotech, and life sciences innovation, providing access to top talent, investors, and collaborative research opportunities.
What’s Next for Xaira?
Xaira is focused on scaling its AI platform for drug discovery, expanding its capabilities in biological and clinical data generation, and accelerating translational research. With its $1B Series D funding, the company aims to enhance R&D productivity, increase drug pipeline success rates, and solidify its position as a leader in AI-driven life sciences innovation.
Get Investor & Funding Insights with TexAu
TexAu helps teams uncover detailed fundraising information on companies like Xaira. Use the platform to research investors, track funding rounds, and gather actionable insights to strengthen prospecting and business strategy.
Sign Up for Free on TexAu and start uncovering detailed funding insights that give your business a competitive edge.
